HER2-positive (n = 12), number of patients (%) | HER2-negative (n = 4), number of patients (%) | |
---|---|---|
Median age | 61 | 66 |
ER-positive | 9 (75%) | 3 (75%) |
Site of disease | ||
Locoregional | 4 (33%) | 2 (50%) |
Liver | 9 (75%) | 4 (100%) |
Bone | 8 (67%) | 3 (75%) |
Lung | 2 (17%) | 1 (25%) |
Lymph nodes | 3 (25%) | 1 (25%) |
CNS | 3 (25%) | 2 (50%) |
Contralateral breast | 0 | 1 (25%) |
Other | 4 (33%) | 1 (25%) |
Ongoing treatment with trastuzumab | 11 (92%) | 0 |
Biopsy post-PET | 9 (75%) | 3 (75%) |